Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,018 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.
Sugarman S, Wasserheit C, Hodgman E, Coglianese M, D'Alassandro A, Fornier M, Troso-Sandoval T, D'Andrea G, Drullinsky P, Lake D, George R, Mills N, Moynahan M, Smith J, Panageas K, Norton L, Hudis C. Sugarman S, et al. Among authors: norton l. Breast Cancer Res Treat. 2009 Jun;115(3):609-12. doi: 10.1007/s10549-008-0152-9. Epub 2008 Aug 27. Breast Cancer Res Treat. 2009. PMID: 18751888 Clinical Trial.
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K. Kauff ND, et al. Among authors: norton l. N Engl J Med. 2002 May 23;346(21):1609-15. doi: 10.1056/NEJMoa020119. Epub 2002 May 20. N Engl J Med. 2002. PMID: 12023992 Free article.
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.
Modi S, Panageas KS, Duck ET, Bach A, Weinstock N, Dougherty J, Cramer L, Hudis C, Norton L, Seidman A. Modi S, et al. Among authors: norton l. J Clin Oncol. 2002 Sep 1;20(17):3665-73. doi: 10.1200/JCO.2002.08.057. J Clin Oncol. 2002. PMID: 12202668 Clinical Trial.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Citron ML, et al. Among authors: norton l. J Clin Oncol. 2003 Apr 15;21(8):1431-9. doi: 10.1200/JCO.2003.09.081. Epub 2003 Feb 13. J Clin Oncol. 2003. PMID: 12668651 Clinical Trial.
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Bégin LR, Offit K, Foulkes WD. Robson ME, et al. Among authors: norton l. Breast Cancer Res. 2004;6(1):R8-R17. doi: 10.1186/bcr658. Epub 2003 Oct 24. Breast Cancer Res. 2004. PMID: 14680495 Free PMC article.
1,018 results